Stockreport

CERo Therapeutics, Inc. Announces Publication of Preclinical Research Supporting the Use of Its Clinical Candidate CER-1236 to Treat AML Patients

CERo Therapeutics Holdings, Inc.  (CERO) 
PDF SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--CERo Therapeutics Holdings, Inc., (NASDAQ:CERO) ("CERo") an innovative immunotherapy company seeking to advance the nex [Read more]